Estring: profile and news

Paladin Reports Record 2005 Fourth Quarter and Year End Results ...  Feb 22, 2006
Combined sales of the Company's key promoted brands including, Dostinex(R), Estring(R), Oxytrol(R), Plan B(R) and Twinject(R) increased 34% in the fourth ... - Black Enterprise,

Paladin Reports Record 2005 Fourth Quarter and Year End Results ...  Feb 22, 2006
Combined sales of the Company's key promoted brands including, Dostinex ® , Estring ® , Oxytrol ® , Plan B ® and Twinject ® increased 34% in the fourth ... - CCNMatthews (press release),

Breast Cancer: Topical Estrogen Risky  Jan 26, 2006
...estrogen. Commonly used vaginal estrogen products include Estrace and Premarin creams, and Estring and Femring vaginal rings. "We ... - WebMD

Hormones given through the skin are worth a look  11 Dec 2005
There are also FDA-approved vaginal rings that deliver estradiol, one called Estring which only combats vaginal dryness; and another called Femring, which ... - Boston Globe,

Paladin Reports Record Revenue for Third Quarter: Sales of Key ...  Oct 27, 2005
Revenue from the Company's key promoted brands including, Dostinex ® , Estring ® , Oxytrol ® , Plan B ® and Twinject TM increased by 61% in the first nine ... - CCNMatthews (press release),

Menopause In Women - Part II  Oct 18, 2005
...work. These include rings such as Estring, creams such as Estrace, and Premarin, and tablets such as Vagifem and Premarin. Vitamin ... - The Bahama Journal,

Paladin Reports 2005 Second Quarter Results-Paladin Increases 2005 ...  Jul 28, 2005
..."Paladin achieved record-breaking prescription volumes in the quarter on all four of our key promoted brands, including Dostinex(R), Estring(R), Oxytrol(R) and ... - CCNMatthews (press release)

Paladin Reports 2005 First Quarter Financial Results  May 5, 2005
Revenue growth resulted primarily from a 37% increase in sales of the Company’s key promoted brands, including Dostinex®, Estring®, Oxytrol® and Plan B ... - PharmaLive.com,

Paladin reports 2004 fourth quarter and year end results  Feb 17, 2005
...increased to $3.2 million, up from a net loss of $4.2 million in 2003 - Sales of the Company's key promoted brands including, Dostinex(R), Estring(R), Oxytrol(R ... - Canada NewsWire (press release),

D. Drug and Laboratory Test Interactions

1. Accelerated prothrombin time, partial thromboplastin time, and platelet aggregation time; increased platelet count; increased factors II, VII antigen, VIII antigen, VIII coagulant activity, IX, X, XII, VII-X complex, II-VII-X complex, and beta-thromboglobulin; decreased levels of anti-factor Xa and antithrombin III, decreased antithrombin III activity; increased levels of fibrinogen and fibrinogen activity; increased plasminogen antigen and activity.

2. Increased thyroid-binding globulin (TBG) leading to increased circulating total thyroid hormone levels, as measured by protein-bound iodine (PBI), T₄ levels (by column or by radioimmunoassay) or T₃ levels by radioimmunoassay. T₃ resin uptake is decreased, reflecting the elevated TBG. Free T₄ and T₃ concentrations are unaltered. Patients on thyroid replacement therapy may require higher doses of thyroid hormone.

3. Other binding proteins may be elevated in serum, i.e., corticosteroid binding globulin (CBG), sex hormone-binding globulin (SHBG), leading to increased total circulating corticosteroids and sex steroids, respectively. Free hormone concentrations may be decreased. Other plasma proteins may be increased (angiotensinogen/renin substrate, alpha-1-antitrypsin, ceruloplasmin).

4. Increased plasma HDL and HDL₂ cholesterol subfraction concentrations, reduced LDL cholesterol concentration, increased triglyceride levels.

5. Impaired glucose tolerance.

6. Reduced response to metyrapone test.